Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica.
Rheum Dis Clin North Am
; 50(2): 255-267, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38670724
ABSTRACT
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polymyalgia Rheumatica
/
Immune Checkpoint Inhibitors
Limits:
Humans
Language:
En
Journal:
Rheum Dis Clin North Am
Journal subject:
REUMATOLOGIA
Year:
2024
Document type:
Article